Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Manoj P Samant

Soumitra S Ghosh

Mary Erickson

David C Litzinger

Zijian Guo

Abhinandini Sharma

Lala Mamedova

Odile Esther Levy

Christopher Joseph Soares

Chengzao Sun

Caroline Ekblad

Swetha Neravetla

Esther Odile Levy

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Growing community of inventors

Boston, MA, United States of America

Manoj P Samant